Gregory John Dore

Prof. Gregory John Dore

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2005 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
JMJ. M. Micallef
J. M. Micallef
JKJ. M. Kaldor
J. M. Kaldor
GDGregory John Dore
Gregory John Dore

1 October 2001 in Hepatology
Verified
Journal Article
Open access
PDF file
AFAnthony J. Freeman
Anthony J. Freeman
GDGregory John Dore
Gregory John Dore
MLMatthew G. Law
Matthew G. Law
MTMax Thorpe
Max Thorpe
JOJan Von Overbeck
Jan Von Overbeck
JKJohn M. Kaldor
John M. Kaldor
To gain a clearer understanding of the rate of progression to cirrhosis and its determinants in chronic hepatitis C virus (HCV) infection, a systematic review of published epidemiologic studies that incorporated assessment for cirrhosis has been undertaken. Inclusion criteria were more than 20 cases of chronic HCV infection, and information on either age of subjects or duration of infection. Of 145 studies examined, 57 fulfilled the inclusion criteria. Least-squares linear regression was employed to estimate rates of progression to cirrhosis, and to examine for factors associated with more rapid disease progression in 4 broad study categories: 1) liver clinic series (number of studies = 33); 2) posttransfusion cohorts (n = 5); 3) blood donor series (n = 10); and 4) community-based cohorts (n = 9). Estimates of progression to cirrhosis after 20 years of chronic HCV infection were 22% (95% CI, 18%-26%) for liver clinic series, 24% (11%-37%) for posttransfusion cohorts, 4% (1%-7%) for blood donor series, and 7% (4%-10%) for community-based cohorts. Factors that were associated with more rapid disease progression included older age at HCV infection, male gender, and heavy alcohol intake. Even after accounting for these factors, progression estimates were much higher for cross-sectional liver clinic series. Selection biases probably explain the higher estimates of disease progression in this group of studies. Community-based cohort studies are likely to provide a more representative basis for estimating disease progression at a population level. These suggest that for persons who acquire HCV infection in young adulthood, less than 10% are estimated to develop cirrhosis within 20 years. (Hepatology 2001;34:809-816.)

1 July 1999 in AIDS
Verified
Journal Article
Closed access
GDGregory John Dore
Gregory John Dore
PCPatricia K. Correll
Patricia K. Correll
YLYueming Li
Yueming Li
JKJohn M. Kaldor
John M. Kaldor
DCDavid A. Cooper
David A. Cooper
BBBruce J. Brew
Bruce J. Brew
To determine the protective efficacy of highly active antiretroviral therapy (HAART) against AIDS dementia complex (ADC) relative to other initial AIDS-defining illnesses (ADIs), Australian AIDS notification data over recent years were examined. All initial ADIs in Australia over the period 1992-1997 were included. Three initial ADI groups were established: ADC; other predominantly central nervous system (CNS) ADIs (toxoplasmosis and cryptococcosis); and non-CNS ADIs. For each ADI grouping, the proportion of total ADIs, and median CD4 cell count in the pre-HAART era (1992-1995) were compared with the HAART era (1996 and 1997). Initial ADIs peaked in Australia in 1994 (n=1049), with a gradual decline to 1996 (n=722), and a marked decline in 1997 (n=367). ADC constituted 4.4% of initial ADIs over the period 1992-1995, but increased after the introduction of HAART to 6.0% in 1996 and 6.5% in 1997 (P=0.02). In contrast, the proportion of other CNS ADIs (1992-1995, 8.1%; 1996, 6.0%; 1997, 8.2%; P=0.41) was stable over the period 1992-1997. The median CD4 cell count at ADC diagnosis increased from 70/mm3 in 1992-1995 to 120/mm3 in 1996 and 170/mm3 in 1997 (P=0.04). Although the median CD4 cell count also increased significantly over this period for both other CNS ADIs (40-60/mm3; P=0.02), and non-CNS ADIs (60-70/mm3; P=0.02), the increase was small. A proportional increase in ADC compared with other ADIs and a marked increase in the median CD4 cell count at ADC diagnosis have occurred since the introduction of HAART in Australia. These changes suggest that HAART has a lesser impact on ADC than on other ADIs, with the poor CNS penetration of many antiretroviral agents a possible explanation.

9 August 2016 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
GDGregory John Dore
Gregory John Dore
FAFrederick Altice
Frederick Altice
ALAlain H. Litwin
Alain H. Litwin
ODOlav Dalgard
Olav Dalgard
EGEdward J. Gane
Edward J. Gane
OGon behalf of the C-EDGE CO-STAR Study Group
on behalf of the C-EDGE CO-STAR Study Group
Hepatitis C virus (HCV) infection is common in persons who inject drugs (PWID). To evaluate elbasvir-grazoprevir in treating HCV infection in PWID. Randomized, placebo-controlled, double-blind trial. (ClinicalTrials.gov: NCT02105688). Australia, Canada, France, Germany, Israel, the Netherlands, New Zealand, Norway, Spain, Taiwan, the United Kingdom, and the United States. 301 treatment-naive patients with chronic HCV genotype 1, 4, or 6 infection who were at least 80% adherent to visits for opioid agonist therapy (OAT). The immediate-treatment group (ITG) received elbasvir-grazoprevir for 12 weeks; the deferred-treatment group (DTG) received placebo for 12 weeks, no treatment for 4 weeks, then open-label elbasvir-grazoprevir for 12 weeks. The primary outcome was sustained virologic response at 12 weeks (SVR12), evaluated separately in the ITG and DTG. Other outcomes included SVR24, viral recurrence or reinfection, and adverse events. The SVR12 was 91.5% (95% CI, 86.8% to 95.0%) in the ITG and 89.5% (95% CI, 81.5% to 94.8%) in the active phase of the DTG. Drug use at baseline and during treatment did not affect SVR12 or adherence to HCV therapy. Among 18 patients with posttreatment viral recurrence through 24-week follow-up, 6 had probable reinfection. If the probable reinfections were assumed to be responses, SVR12 was 94.0% (CI, 89.8% to 96.9%) in the ITG. One patient in the ITG (1 of 201) and 1 in the placebo-phase DTG (1 of 100) discontinued treatment because of an adverse event. These findings may not be generalizable to PWID who are not receiving OAT, nor do they apply to persons with genotype 3 infection, a common strain in PWID. Patients with HCV infection who were receiving OAT and treated with elbasvir-grazoprevir had high rates of SVR12, regardless of ongoing drug use. These results support the removal of drug use as a barrier to interferon-free HCV treatment for patients receiving OAT. Merck & Co.

23 July 2018 in Addiction
Verified
Journal Article
Open access
PDF file
JGJason Grebely
Jason Grebely
SLSarah Larney
Sarah Larney
APAmy Peacock
Amy Peacock
SCSamantha Colledge
Samantha Colledge
Janni LeungJanni Leung
Janni Leung
LDLouisa Degenhardt
Louisa Degenhardt
Background and Aims: People who have recently injected drugs are a priority population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living with HCV, and the proportion of people with recent injecting drug use among all people living with HCV infection at global, regional and country‐levels.Methods: Data from a global systematic review of injecting drug use and HCV antibody prevalence among people with recent (previous year) injecting drug use were used to estimate the prevalence and number of people with recent injecting drug use living with HCV. These data were combined with a systematic review of global HCV prevalence to estimate the proportion of people with recent injecting drug use among all people living with HCV.Results: There are an estimated 6.1 million [95% uncertainty interval (UI) = 3.4–9.2] people with recent injecting drug use aged 15–64 years living with HCV globally (39.2% viraemic prevalence; UI = 31.6–47.0), with the greatest numbers in East and Southeast Asia (1.5 million, UI = 1.0–2.1), eastern Europe (1.5 million, UI = 0.7–2.4) and North America (1.0 million, UI = 0.4–1.7). People with recent injecting drug use comprise an estimated 8.5% (UI = 4.6–13.1) of all HCV infections globally, with the greatest proportions in North America (30.5%, UI = 11.7–56.7), Latin America (22.0%, UI = 15.3–30.4) and eastern Europe (17.9%, UI = 8.2–30.9).Conclusions: Although, globally, 39.2% of people with recent injecting drug use are living with hepatitis C virus (HCV) and 8.5% of all HCV infections occur globally among people with recent injecting drug use, there is wide variation among countries and regions.

1 July 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
IJIra M. Jacobson
Ira M. Jacobson
ELEric Lawitz
Eric Lawitz
EGEdward J. Gane
Edward J. Gane
BWBernard E. Willems
Bernard E. Willems
PRPeter J. Ruane
Peter J. Ruane
GFGraham R. Foster
Graham R. Foster